A First-In-Human Study With a Single Ascending Dose of UCB7858 in Healthy Volunteers

Healthy Volunteers Clinical Trial

Official title:

A Subject-blind, Investigator-blind, Randomized, Placebo-controlled, First-in-human Study Evaluating the Safety/Tolerability, Pharmacokinetics, Effect on Transglutaminase 2 Expression, and Occupancy of Single Ascending Intravenous and Subcutaneous Doses of UCB7858 in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02879877
• Other study ID #: UP0029
• Secondary ID: 2016-001129-15
• Status: Completed
• Phase: Phase 1
• Start date: July 11, 2016
• Est. completion date: January 31, 2018

Study information

• Verified date: August 2019
• Source: UCB Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to evaluate the safety and tolerability of UCB7858 when given as single ascending doses administered by intravenous or subcutaneous infusion in healthy subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 78
• Est. completion date: January 31, 2018
• Est. primary completion date: January 31, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Healthy male and female volunteers who gave their written consent by signing the Informed Consent Form

• Subjects in the age between 18 and 55 years old with normal weight as determined by a body mass index (BMI) between 18 and 30 kg/m^2, with a body weight of at least 50 kg for male subjects or 45 kg for female subjects

• Subject has clinical laboratory test results within the reference ranges of the testing laboratory or outside the reference range of the laboratory but considered as not clinically significant by the Investigator

• Subjects has blood pressure (BP) and pulse within normal range in a supine position after 5 minutes rest

• Subject's electrocardiogram (ECG) is considered normal or abnormal but clinically non significant

• Female subjects of childbearing potential must agree to use a highly effective method of birth control during the study and for a period of 6 months after dosing of IMP

Exclusion Criteria:

• Subject has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study: Subject has any acute or chronic illness which, in the opinion of the Investigator, may place the subject at risk because of participation in the study. Subject has any clinically relevant abnormal findings in physical examination, laboratory tests, vital signs, or ECG, which, in the opinion of the Investigator, may place the subject at risk because of participation in the study.

• Tests positive for Human Immunodeficiency Virus (HIV)-1 or-2 antibodies, Hepatitis B Virus (HBV) surface antigen, or Hepatitis C Virus (HCV) antibody at Screening

• Any of the following hematological function tests at the Screening Visit: Hemoglobin <111g/L (for women) or <113g/L (for men)

• Absolute neutrophil count <1.5x10^9/L (<1000/mm^3); Platelets <150x10^9/L

• Female subject who is breastfeeding, pregnant, or plans to become pregnant during the study or within 6 months following the final dose of the IMP

For subjects enrolled in the cohorts where the skin biopsies will be performed (Cohort 7 onward), the following exclusion criteria will also apply:

• Subject has a known hypersensitivity to dressings, local anesthetics, suture material, or relevant local/oral antibiotic therapy

• Subject has or had a history of a known inflammatory dermatological condition including eczema, atopic dermatitis, candidiasis, psoriasis, recurrent or persistent fungal infection, or bacterial infections

• Subject uses steroid or nonsteroidal anti-inflammatory drug (NSAID)-containing skin creams on a regular basis

• Subject has used NSAID or NSAID-containing medications within 7 days of randomization

• Subject has used skin emollients within 7 days of randomization on the area of the skin from buttocks

• Subject has tattoos, nevi, or other skin abnormalities such as keloids (or history of keloids, folliculitis, or acne vulgaris) that may, in the opinion of the Investigator, interfere with study assessments.

• Subject has been participating in recreational sun-bathing, or use of sun-bed, on the area of the skin from buttocks within 7 days of Screening

• Subject has active neoplastic disease or history of neoplastic disease within 5 years of the Screening Visit

• Subject has a history of moderate to severe allergic reaction to medication(s) including biologics (for subjects in Cohort 11 only).

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• UCB7858

• Placebo

Locations

Country	Name	City	State
United Kingdom	Up0029 001	London

Sponsors (1)

Lead Sponsor	Collaborator
UCB Biopharma S.P.R.L.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events following administration of UCB7858		Cohort 1-10: Day 1 up to Day 72 Cohort 11: Day 1 up to Day 120
Secondary	Maximum plasma concentration (Cmax)		Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120
Secondary	Time to reach Cmax (tmax)		Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120
Secondary	Area under the curve from time 0 to time t, the time of last quantifiable concentration [AUC(0-t)]		Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120
Secondary	Area under the curve from 0 to infinity (AUC)		Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120
Secondary	The terminal plasma half-life (t1/2) following intravenous administration		Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120
Secondary	Plasma clearance (CL) of UCB7858 following intravenous administration		Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120
Secondary	Volume of distribution (Vss) for UCB7858 at steady state following intravenous administration		Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120
Secondary	Apparent volume of distribution (Vss/F) of UCB7858 following subcutaneous administration		Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120
Secondary	Apparent plasma clearance (CL/F) of UCB7858 following subcutaneous administration		Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120
Secondary	Mean absolute bioavailability (F) of UCB7858 given subcutaneously, using the ratio of geometric mean AUCs for subcutaneous (sc) administration and intravenous (iv) infusion (AUC_sc/AUC_iv)		Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120
Secondary	Concentration of UCB7858 at the end of infusion (Cinf)		Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120
Secondary	Time at the end of infusion of UCB7858 (tinf)		Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120